• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Apollomics

Monday, June 03, 2024
CP
Oncology
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
Apollomics
Company Website: http://www.apollomicsinc.com
Lead Product in Development: Vebreltinib

Exchange

Nasdaq

Ticker

APLM

Company HQ City

Foster City

Company HQ State

California

Company HQ Country

United States

CEO/Top Company Official

Guo Liang Yu

Development Phase of Primary Product

Phase II
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS